ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 270 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,945,143 | -20.6% | 93,337 | -8.8% | 0.00% | 0.0% |
| Q2 2023 | $2,451,067 | -0.0% | 102,341 | -21.4% | 0.00% | 0.0% |
| Q1 2023 | $2,451,136 | +48553.0% | 130,241 | -58.8% | 0.00% | 0.0% |
| Q4 2022 | $5,038 | -99.9% | 316,464 | -11.2% | 0.00% | -50.0% |
| Q3 2022 | $5,830,000 | -16.1% | 356,415 | -27.7% | 0.00% | 0.0% |
| Q2 2022 | $6,946,000 | -55.3% | 492,928 | -23.1% | 0.00% | -60.0% |
| Q1 2022 | $15,531,000 | +0.8% | 641,223 | -2.9% | 0.01% | 0.0% |
| Q4 2021 | $15,411,000 | +217.8% | 660,252 | +126.2% | 0.01% | +150.0% |
| Q3 2021 | $4,850,000 | -35.0% | 291,887 | -4.6% | 0.00% | 0.0% |
| Q2 2021 | $7,462,000 | -18.0% | 305,996 | -13.3% | 0.00% | -33.3% |
| Q1 2021 | $9,102,000 | -49.5% | 352,817 | +4.6% | 0.00% | -57.1% |
| Q4 2020 | $18,025,000 | +33.6% | 337,147 | +3.0% | 0.01% | +16.7% |
| Q3 2020 | $13,493,000 | -10.7% | 327,217 | +4.9% | 0.01% | -14.3% |
| Q2 2020 | $15,116,000 | +22.8% | 311,907 | +7.0% | 0.01% | +16.7% |
| Q1 2020 | $12,306,000 | -2.9% | 291,404 | -1.6% | 0.01% | +20.0% |
| Q4 2019 | $12,674,000 | +185.5% | 296,224 | +140.2% | 0.01% | +150.0% |
| Q3 2019 | $4,440,000 | +1175.9% | 123,303 | +968.2% | 0.00% | – |
| Q4 2017 | $348,000 | -89.5% | 11,543 | -86.9% | 0.00% | -100.0% |
| Q3 2017 | $3,308,000 | -51.6% | 87,795 | -55.8% | 0.00% | -66.7% |
| Q1 2017 | $6,828,000 | +3003.6% | 198,620 | +2500.1% | 0.00% | – |
| Q4 2016 | $220,000 | -96.9% | 7,639 | -96.6% | 0.00% | -100.0% |
| Q3 2016 | $7,171,000 | +65.6% | 225,404 | +68.9% | 0.00% | +100.0% |
| Q2 2016 | $4,331,000 | -19.4% | 133,426 | -11.4% | 0.00% | -33.3% |
| Q4 2015 | $5,372,000 | +9.1% | 150,666 | +1.2% | 0.00% | 0.0% |
| Q3 2015 | $4,922,000 | -17.3% | 148,927 | +4.8% | 0.00% | -25.0% |
| Q2 2015 | $5,950,000 | +59.0% | 142,130 | +23.8% | 0.00% | +100.0% |
| Q1 2015 | $3,741,000 | +104.8% | 114,765 | +99.4% | 0.00% | +100.0% |
| Q4 2014 | $1,827,000 | -58.8% | 57,541 | -67.6% | 0.00% | -66.7% |
| Q4 2013 | $4,434,000 | – | 177,433 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |